Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730for the Treatment of Dyskinesia in Parkinson's Disease
The FJORD study was a double-blind, randomized, placebo-controlled, multiple dose-escalating study of the safety, tolerability and efficacy of JP-1730/fipamezole in the treatment of levodopa-induced dyskinesia in Parkinson's Disease patients. The study investigated the efficacy of three doses (30, 60 and 90 mg) compared to placebo over a treatment period of 28 days in 179 patients enrolled at a total of 33 sites in the US (26) and India (7). The primary study endpoint was the suppression of levodopa-induced dyskinesia as measured by the Levodopa Induced Dyskinesia Scale (LIDS). The LIDS is a modified version of the Abnormal Involuntary Movement Scale, an evaluation tool widely used in clinical research.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.